Advertisement
SHC vs TMO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SHC is a Hold and TMO is a Hold.
SHC's Indicator enters downward trend
The Aroon Indicator for SHC entered a downward trend on October 19, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator formed such a pattern. In 170 of the 210 cases the stock moved lower. This puts the odds of a downward move at 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SHC as a result. In 54 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
SHC moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SHC crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where SHC advanced for three days, in 187 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
SHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating fairly steady price growth. SHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.618) is normal, around the industry mean (64.450). P/E Ratio (31.175) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (1.313) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 62 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TMO just turned positive on October 16, 2026. Looking at past instances where TMO's MACD turned positive, the stock continued to rise in 28 of 43 cases over the following month. The odds of a continued upward trend are 65%.
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 194 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 143 of 246 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 22 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.871) is normal, around the industry mean (64.450). P/E Ratio (37.293) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
SHC | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 76 | |
SMR RATING 1..100 | 35 | 60 | |
PRICE GROWTH RATING 1..100 | 48 | 8 | |
P/E GROWTH RATING 1..100 | 96 | 23 | |
SEASONALITY SCORE 1..100 | 16 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (65) in the Medical Specialties industry is in the same range as SHC (74) in the null industry. This means that TMO’s stock grew similarly to SHC’s over the last 12 months.
TMO's Profit vs Risk Rating (76) in the Medical Specialties industry is in the same range as SHC (100) in the null industry. This means that TMO’s stock grew similarly to SHC’s over the last 12 months.
SHC's SMR Rating (35) in the null industry is in the same range as TMO (60) in the Medical Specialties industry. This means that SHC’s stock grew similarly to TMO’s over the last 12 months.
TMO's Price Growth Rating (8) in the Medical Specialties industry is somewhat better than the same rating for SHC (48) in the null industry. This means that TMO’s stock grew somewhat faster than SHC’s over the last 12 months.
TMO's P/E Growth Rating (23) in the Medical Specialties industry is significantly better than the same rating for SHC (96) in the null industry. This means that TMO’s stock grew significantly faster than SHC’s over the last 12 months.
| SHC | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 58% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 70% |
| MACD ODDS (%) | N/A | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 62% |
| Advances ODDS (%) | 10 days ago 68% | 2 days ago 63% |
| Declines ODDS (%) | 4 days ago 70% | 4 days ago 62% |
| BollingerBands ODDS (%) | 2 days ago 69% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SHC’s FA Score shows that 0 FA rating(s) are green while TMO’s FA Score has 2 green FA rating(s).
- SHC’s FA Score: 0 green, 5 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SHC’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- SHC’s TA Score: 3 bullish, 5 bearish.
- TMO’s TA Score: 4 bullish, 4 bearish.
Price Growth
SHC (@Medical Specialties) experienced а +0.23% price change this week, while TMO (@Medical Specialties) price change was +3.09% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.63%. For the same industry, the average monthly price growth was -7.00%, and the average quarterly price growth was +41.94%.
Reported Earning Dates
SHC is expected to report earnings on Nov 03, 2026.
TMO is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Medical Specialties (-3.63% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
SHC and
Correlation & Price change
A.I.dvisor indicates that over the last year, SHC has been loosely correlated with RVTY. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SHC jumps, then RVTY could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | +0.97% | ||
| A - TMO | 74% Closely correlated | +2.74% | ||
| DHR - TMO | 71% Closely correlated | +4.29% | ||
| RVTY - TMO | 70% Closely correlated | +0.38% | ||
| IQV - TMO | 68% Closely correlated | +3.28% | ||
| BRKR - TMO | 67% Closely correlated | +5.68% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VTES | 99.64 | 0.04 | +0.04% |
| Vanguard Short-Term Tax Exempt Bond ETF (VTES) | |||
| CPSD | 27.26 | N/A | N/A |
| Calamos S&P 500 Structured Alt Protection ETF - December (CPSD) | |||
| FAB | 103.69 | -0.18 | -0.17% |
| First Trust Multi Cap Value AlphaDEX Fund (FAB) | |||
| SPCK | 21.45 | -0.17 | -0.81% |
| SPAC and New Issue ETF (SPCK) | |||
| EPU | 88.71 | -0.76 | -0.85% |
| iShares MSCI Peru and Global Exposure ETF (EPU) | |||